VASODILATOR EFFECTS OF VISNAGIN IN ISOLATED RAT VASCULAR SMOOTH-MUSCLE

被引:48
作者
DUARTE, J
PEREZVIZCAINO, F
TORRES, AI
ZARZUELO, A
JIMENEZ, J
TAMARGO, J
机构
[1] UNIV COMPLUTENSE MADRID,SCH MED,DEPT PHARMACOL,E-28040 MADRID,SPAIN
[2] UNIV GRANADA,SCH PHARM,DEPT PHARMACOL,E-18071 GRANADA,SPAIN
关键词
VISNAGIN; AORTA; RAT; PORTAL VEIN;
D O I
10.1016/0014-2999(95)00418-K
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Visnagin (4-methoxy-7-methyl-5H-furo [3,2-g][1]-benzopyran-5-one) is an active principle of the fruit of Ammi visnaga, a plant traditionally used in cardiovascular disorders. We have studied its vasodilator effects in rat vascular smooth muscle. The results demonstrated that visnagin inhibited the contractile responses induced in rat aortic rings by: (a) KCl or increases of extracellular Ca2+ in KCl depolarized aortic rings, its effects being more potent against low (20 mM) than high (80 mM) KCl-induced contractions, (b) noradrenaline in Ca2+-containing solution and less effectively those in Ca2+-free solution and (c) phorbol 12-myristate 13-acetate (PMA) in a Ca2+-containing and with a lower potency in Ca2+-free medium. The relaxation induced by visnagin in aorta precontracted with noradrenaline was not affected by endothelium removal. Additionally, visnagin inhibited the spontaneous myogenic contractions of portal veins. The results showed that visnagin inhibited vascular smooth muscle contractility by acting at multiple sites. In the range of 10(-6) M to 5 X 10(-5) M visnagin appears to inhibit only the contractions mediated by Ca2+ entry through pathways with low sensitivity to classical Ca2+-entry blockers, i.e. agonist-, PMA-or mild depolarization-induced Ca2+ entry. Therefore, the vasodilator profile of visnagin, is not that of typical Ca2+-entry blockers which preferentially inhibit the contractions induced by strong depolarizations.:At higher concentrations (>5 x 10(-5) M) visnagin causes non-specific inhibition of vascular smooth muscle contractility.
引用
收藏
页码:115 / 122
页数:8
相关论文
共 25 条
[1]   PROTEIN-KINASE-C OF SMOOTH-MUSCLE [J].
ANDREA, JE ;
WALSH, MP .
HYPERTENSION, 1992, 20 (05) :585-595
[2]  
ANREP GV, 1946, BRIT HEART J, V8, P171
[3]   THE CORONARY VASODILATOR ACTION OF KHELLIN [J].
ANREP, GV ;
KENAWY, MR ;
BARSOUM, GS .
AMERICAN HEART JOURNAL, 1949, 37 (04) :531-542
[4]  
ASHCROFT FM, 1988, ANNU REV NEUROSCI, V11, P763
[5]  
CAUVIN C, 1984, J PHARMACOL EXP THER, V230, P413
[6]   MECHANISMS OF CALCIUM ANTAGONIST-INDUCED VASODILATION [J].
CAUVIN, C ;
LOUTZENHISER, R ;
VANBREEMEN, C .
ANNUAL REVIEW OF PHARMACOLOGY AND TOXICOLOGY, 1983, 23 :373-396
[7]  
Charlier R., 1971, ANTIANGINAL DRUGS, P118
[8]  
CHIU AT, 1987, J PHARMACOL EXP THER, V240, P123
[9]   EFFECTS OF CALCIUM ENTRY BLOCKERS ON CALCIUM-DEPENDENT CONTRACTIONS OF RAT PORTAL-VEIN [J].
DACQUET, C ;
MIRONNEAU, C ;
MIRONNEAU, J .
BRITISH JOURNAL OF PHARMACOLOGY, 1987, 92 (01) :203-211
[10]   INHIBITORY EFFECTS OF QUERCETIN AND STAUROSPORINE ON PHASIC CONTRACTIONS IN RAT VASCULAR SMOOTH-MUSCLE [J].
DUARTE, J ;
PEREZVIZCAINO, F ;
ZARZUELO, A ;
JIMENEZ, J ;
TAMARGO, J .
EUROPEAN JOURNAL OF PHARMACOLOGY, 1994, 262 (1-2) :149-156